Markets:

Overview

News

Currencies

International

Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

32.59 -0.65 (-1.94%)

Streaming Delayed Price Updated: 2:32 PM EDT, Jul 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? ↗

Today 12:32 EDT

Novartis boasts a 26% net margin and a fortress balance sheet, while Teva's turnaround has returned it to profitability, but at what cost to stability?

Via The Motley Fool

Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? ↗

July 06, 2026

Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.

Via The Motley Fool

Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain? ↗

June 19, 2026

Teva has been building its comeback, and the latest studies on Austedo and Austedo XR will help further that momentum.

Via The Motley Fool

TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) Flags Technical Breakout Setup with Top Ratings ↗

May 30, 2026

Via Chartmill

June 12, 2026

Driving revenue growth and earnings growth are two different things.

Via The Motley Fool

Topics Intellectual Property

Teva Pharmaceutical Industries Just Pulled Off One of Pharma's Most Impressive Comebacks ↗

June 01, 2026

Teva's transformation is gaining momentum.

Via The Motley Fool

Teva Stock Is at Its Highest Level in Nearly a Decade. Here's Why It Could Soar Even More. ↗

May 15, 2026

The market's rediscovery of Teva Pharmaceuticals remains ongoing.

Via The Motley Fool

Wall Street Thinks Teva Stock Still Has Room to Run After Soaring Over 100%. Here's Why Analysts Are Right. ↗

May 14, 2026

Teva's turnaround is real -- and may not be over.

Via The Motley Fool

Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't? ↗

April 30, 2026

A significant financing deal with Blackstone underscores that the Teva of today isn't the Teva of the past.

Via The Motley Fool

Teva Pharmaceutical's Turnaround Is Working. Here's When to Buy the Stock. ↗

April 27, 2026

That's when its first-quarter results will be published.

Via The Motley Fool

3 Catalysts That Could Send Teva Stock to $40 and Beyond ↗

April 18, 2026

This once-beaten-down pharma stock remains an intriguing turnaround story.

Via The Motley Fool

Neurocrine Biosciences (NBIX): A New Era in Neuroscience and Endocrinology

April 07, 2026

Date: April 7, 2026 Introduction Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has long been a bellwether for the mid-cap biotechnology sector, serving as a primary case study in how a company can...

Via Finterra

Topics Earnings Economy Intellectual Property

Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally

March 31, 2026

In a month characterized by macroeconomic headwinds and a broader cooling of the biotechnology sector, Corcept Therapeutics (NASDAQ: CORT) has emerged as a definitive outlier. While the S&P Biotech ETF...

Via MarketMinute

Topics ETFs Intellectual Property Stocks

MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough

March 26, 2026

The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the...

Via MarketMinute

Topics Intellectual Property

The Second Act: A Deep-Dive into Corcept Therapeutics and the FDA Approval of Lifyorli

March 26, 2026

March 26, 2026 Introduction Yesterday, March 25, 2026, Corcept Therapeutics (NASDAQ: CORT) reached a defining milestone that has fundamentally altered its investment profile: the early FDA approval of...

Via Finterra

Topics Economy Intellectual Property

This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition ↗

March 22, 2026

Masimo develops advanced noninvasive monitoring technologies used by hospitals and healthcare providers worldwide.

Via The Motley Fool

The $1.3 Trillion Architect: How Blackstone is Redefining Global Finance through Private Credit and Essential Consumerism

March 18, 2026

By Finterra Editorial TeamMarch 18, 2026 Introduction In the high-stakes world of global alternative asset management, one name looms larger than the rest: Blackstone Inc. (NYSE: BX). As of March 18,...

Via Finterra

Topics Artificial Intelligence Economy Energy

Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment ↗

March 13, 2026

This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned ↗

March 13, 2026

This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications.

Via The Motley Fool

Topics Regulatory Compliance

The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)

March 10, 2026

As of March 10, 2026, the biopharmaceutical sector is witnessing a historic realignment in the neurology space, spearheaded by the Canadian-born clinical powerhouse Xenon Pharmaceuticals Inc. (Nasdaq:...

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

The 3 Best Stocks to Invest $1,000 in Right Now ↗

March 06, 2026

These three high-quality stocks have ample growth potential.

Via The Motley Fool

Topics Artificial Intelligence

Forget Teva: This Dividend Top Dog Is the Real Value Buy Today ↗

March 04, 2026

Teva is undergoing a major business transition, but dividend investors should check out this 6.3% yielding competitor instead.

Via The Motley Fool

Topics Intellectual Property

Billionaire Stanley Druckenmiller Dumped 2 of His Top Performers -- Teva and Taiwan Semiconductor -- and Made This Sector-Based ETF His Fund's New No. 2 Holding ↗

March 04, 2026

Duquesne Family Office's billionaire boss meaningfully pared down two high-flying stocks in the fourth quarter and made a $301 million wager on a popular sector-based exchange-traded fund (ETF).

Via The Motley Fool

Topics Artificial Intelligence ETFs Retirement

Viatris (VTRS): From Debt-Laden Merger to Specialty Powerhouse—A 2026 Research Deep Dive

March 03, 2026

As of March 3, 2026, Viatris Inc. (NASDAQ: VTRS) stands at a pivotal crossroads in its corporate evolution. Formed less than six years ago through one of the most complex healthcare mergers in recent...

Via Finterra

Topics Economy Initial Public Offering Retirement

The Best Healthcare Stock to Invest $1,000 in Right Now ↗

March 02, 2026

There's nothing generic about this drugmaker's recent performance and continued prospects.

Via The Motley Fool

Here's Why I Won't Touch Teva Pharmaceutical With a 10‑Foot Pole ↗

February 27, 2026

Sorry, Teva, it's not you ... it's me.

Via The Motley Fool

Topics Intellectual Property

The Pivot to Growth: Viatris (VTRS) Enters Phase 2 with 2026 Dividend and Capital Allocation Strategy

February 26, 2026

As of February 26, 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a defining crossroads. For years, the company was viewed by many on Wall Street as a "value trap"—a debt-laden giant formed from the...

Via Finterra

Topics Economy

Bridger Dumps 301,000 Bath & Body Works Shares Worth $7.7 Million ↗

February 24, 2026

This specialty retailer delivers personal care and home fragrance products through a broad network of stores and online channels.

Via The Motley Fool

Topics Economy Regulatory Compliance

Inside a $75 Million Albertsons Stock Sale as Shares Sink 8% in a Year ↗

February 20, 2026

Albertsons operates a nationwide grocery network, pairing in-house food production with a broad mix of retail and pharmacy services.

Via The Motley Fool

Topics Regulatory Compliance

AvePoint Stock Down 47% as One Fund Slashes Stake by $65.9 Million ↗

February 20, 2026

This technology firm offers cloud-based data management and compliance tools for organizations using Microsoft 365 and other platforms.

Via The Motley Fool

Topics Regulatory Compliance

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.